» Articles » PMID: 24253315

A Novel Molecular Pathway for Snail-dependent, SPARC-mediated Invasion in Non-small Cell Lung Cancer Pathogenesis

Overview
Specialty Oncology
Date 2013 Nov 21
PMID 24253315
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Definition of the molecular pathogenesis of lung cancer allows investigators an enhanced understanding of the natural history of the disease, thus fostering development of new prevention strategies. In addition to regulating epithelial-to-mesenchymal transition (EMT), the transcription factor Snail exerts global effects on gene expression. Our recent studies reveal that Snail is upregulated in non-small cell lung cancer (NSCLC), is associated with poor prognosis, and promotes tumor progression in vivo. Herein, we demonstrate that overexpression of Snail leads to the upregulation of secreted protein, acidic and rich in cysteine (SPARC) in models of premalignancy and established disease, as well as in lung carcinoma tissues in situ. Snail overexpression leads to increased SPARC-dependent invasion in vitro, indicating that SPARC may play a role in lung cancer progression. Bioinformatic analysis implicates transforming growth factor beta (TGF-β), extracellular signal-regulated kinase (ERK)1/2, and miR-29b as potential intermediaries in Snail-mediated upregulation of SPARC. Both the TGF-β1 ligand and TGF-β receptor 2 (TGF-βR2) are upregulated following Snail overexpression. Treatment of human bronchial epithelial cell (HBEC) lines with TGF-β1 and inhibition of TGF-β1 mRNA expression modulates SPARC expression. Inhibition of MAP-ERK kinase (MEK) phosphorylation downregulates SPARC. MiR-29b is downregulated in Snail-overexpressing cell lines, whereas overexpression of miR-29b inhibits SPARC expression. In addition, miR-29b is upregulated following ERK inhibition, suggesting a Snail-dependent pathway by which Snail activation of TGF-β and ERK signaling results in downregulation of miR-29b and subsequent upregulation of SPARC. Our discovery of pathways responsible for Snail-induced SPARC expression contributes to the definition of NSCLC pathogenesis.

Citing Articles

SPARC: a potential target for functional nanomaterials and drugs.

Jiang S, Sun H, Li S, Zhang N, Chen J, Liu J Front Mol Biosci. 2023; 10:1235428.

PMID: 37577749 PMC: 10419254. DOI: 10.3389/fmolb.2023.1235428.


The role of myokines in cancer: crosstalk between skeletal muscle and tumor.

Park S, Hwang B, Song N BMB Rep. 2023; 56(7):365-373.

PMID: 37291054 PMC: 10390289.


Prognostic significance of SPARC expression in non-small cell lung cancer: A meta-analysis and bioinformatics analysis.

Ma G, Shi S, Zhang Y, Guo Z, Bai W, Zhang Z Oncol Lett. 2022; 24(5):412.

PMID: 36245823 PMC: 9557165. DOI: 10.3892/ol.2022.13532.


Emergence of Resistance to MTI-101 Selects for a MET Genotype and Phenotype in EGFR Driven PC-9 and PTEN Deleted H446 Lung Cancer Cell Lines.

Jones C, Dziadowicz S, Suite S, Eby A, Chen W, Hu G Cancers (Basel). 2022; 14(13).

PMID: 35804837 PMC: 9264848. DOI: 10.3390/cancers14133062.


Paracrine SPARC signaling dysregulates alveolar epithelial barrier integrity and function in lung fibrosis.

Conforti F, Ridley R, Brereton C, Alzetani A, Johnson B, Marshall B Cell Death Discov. 2020; 6:54.

PMID: 32637156 PMC: 7327077. DOI: 10.1038/s41420-020-0289-9.


References
1.
Sato M, Larsen J, Lee W, Sun H, Shames D, Dalvi M . Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations. Mol Cancer Res. 2013; 11(6):638-50. PMC: 3687022. DOI: 10.1158/1541-7786.MCR-12-0634-T. View

2.
Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

3.
Dhasarathy A, Phadke D, Mav D, Shah R, Wade P . The transcription factors Snail and Slug activate the transforming growth factor-beta signaling pathway in breast cancer. PLoS One. 2011; 6(10):e26514. PMC: 3197668. DOI: 10.1371/journal.pone.0026514. View

4.
Kasai H, Allen J, Mason R, Kamimura T, Zhang Z . TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res. 2005; 6:56. PMC: 1177991. DOI: 10.1186/1465-9921-6-56. View

5.
Vicent S, Lopez-Picazo J, Toledo G, Lozano M, Torre W, Garcia-Corchon C . ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Br J Cancer. 2004; 90(5):1047-52. PMC: 2409626. DOI: 10.1038/sj.bjc.6601644. View